Treatment News : BMS’s Attachment Inhibitor Shows Promise

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 20, 2014

BMS’s Attachment Inhibitor Shows Promise

CROI 2014A promising trial of Bristol-Myers Squibb’s investigational attachment inhibitor BMS-663068 raises hope of the introduction of a new antiretroviral drug class, which would especially benefit those with multidrug resistance, aidsmap reports. The randomized, controlled Phase IIb trial evaluated the safety and efficacy of BMS-663068 in 253 treatment-experienced people with HIV who had a viral load of at least 1,000 and a CD4 count above 50, and about half of whom had resistance to at least one ARV drug class. Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The study participants randomly received one of five drug regimens that all contained Viread (tenofovir) and Isentress (raltegravir), plus: either BMS-663068 at 400 milligrams or 800 mg twice a day, or 600 mg or 1,200 mg once a day; or (as a control) ritonavir-boosted Reyataz (atazanavir).

After 24 weeks, the treatment arms containing BMS-663068 were similar in efficacy, with a range of 69 to 80 percent of participants achieving an undetectable viral load. This was compared with 75 percent who did so in the control group. The groups all experienced similar increases in CD4 levels.

BMS-663068 proved generally well tolerated regardless of the dose. There were no indications of safety problems.

To read the BMS press release, click here.

To read the aidsmap story, click here.

Search: BMS-663068, Bristol-Myers Squibb, BMS, drug resistance, Viread, tenofovir, Isentress, raltegravir, Reyataz, atazanavir, fostemsavir

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.